Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2025)

Allogene Therapeutics' Long-Term Investments history runs 8 years deep, the most recent figure standing at $8.0 million for Q4 2025.

• In Q4 2025, Long-Term Investments fell 90.03% year-over-year to $8.0 million; the TTM figure through Dec 2025 stood at $8.0 million (down 90.03% YoY), while the FY2025 annual figure was $8.0 million, down 90.03% from the prior year.
• Long-Term Investments came in at $8.0 million for Q4 2025 at Allogene Therapeutics, down from $24.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $352.2 million in Q4 2021 to a low of $1.1 million in Q2 2024.
• A 5-year average of $56.9 million and a median of $26.3 million in 2022 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments surged 9321.59% in 2021 and slumped 95.08% in 2022, its largest moves.
• Allogene Therapeutics' Long-Term Investments stood at $352.2 million in 2021, then plunged by 95.08% to $17.3 million in 2022, then jumped by 85.77% to $32.2 million in 2023, then surged by 150.77% to $80.7 million in 2024, then tumbled by 90.03% to $8.0 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $8.0 million, $24.9 million, and $29.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison